SEROQUEL Research

AstraZeneca is committed to the development of innovative treatments for diseases and medical conditions designed to improve the health of patients. Clinical research is key to obtaining FDA approval of a medicine as being safe and effective for patients.

Clinical Development Programs

Clinical development programs for SEROQUEL were conducted in an attempt to help address unmet medical needs in the treatment of bipolar disorder and schizophrenia. Our clinical programs broadened the scientific base of knowledge for SEROQUEL and have led to new FDA-approved indications.

In line with our Group Corporate Responsibility Policy on transparency, we are committed to open communication of information on AstraZeneca clinical trials. We provide information about new and ongoing clinical trials sponsored by AstraZeneca.

For more information about AstraZeneca's research and development efforts, including results of clinical trials with SEROQUEL, please visit our corporate Web site. US corporate Web site

Contacting AstraZeneca

For SEROQUEL info:

1-800-236-9933
E-mail

For Media contact only:

Kirsten Evraire
E-mail
302-885-0435

Laura Woodin
E-mail
302-885-1087